Cingulate Net Worth
Cingulate Net Worth Breakdown | CING |
Cingulate Net Worth Analysis
Cingulate's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Cingulate's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Cingulate's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Cingulate's net worth analysis. One common approach is to calculate Cingulate's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Cingulate's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Cingulate's net worth. This approach calculates the present value of Cingulate's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Cingulate's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Cingulate's net worth. This involves comparing Cingulate's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Cingulate's net worth relative to its peers.
To determine if Cingulate is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cingulate's net worth research are outlined below:
| Cingulate had very high historical volatility over the last 90 days | |
| Cingulate has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (23.53 K) with loss before overhead, payroll, taxes, and interest of (15.49 M). | |
| Cingulate currently holds about 8.2 M in cash with (15.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.73. | |
| Cingulate has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Cingulate Inc. adjusts executive compensation - Investing.com |
Cingulate uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cingulate. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cingulate's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Cingulate's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cingulate is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cingulate backward and forwards among themselves. Cingulate's institutional investor refers to the entity that pools money to purchase Cingulate's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wells Fargo & Co | 2024-06-30 | 0.0 | Goalvest Advisory Llc | 2024-09-30 | 0.0 | Qube Research & Technologies | 2024-09-30 | 0.0 | Geode Capital Management, Llc | 2024-09-30 | 0.0 | Jpmorgan Chase & Co | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 0.0 | Virtu Financial Llc | 2024-09-30 | 0.0 | Hrt Financial Llc | 2024-06-30 | 0.0 | Jane Street Group Llc | 2024-09-30 | 21 K | Ubs Group Ag | 2024-09-30 | 13.7 K | Commonwealth Equity Services Inc | 2024-09-30 | 11.3 K |
Follow Cingulate's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 14.62 M.Market Cap |
|
Project Cingulate's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (7.75) | (7.36) | |
| Return On Capital Employed | 3.04 | 3.19 | |
| Return On Assets | (7.75) | (7.36) | |
| Return On Equity | 3.08 | 3.24 |
When accessing Cingulate's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Cingulate's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cingulate's profitability and make more informed investment decisions.
Evaluate Cingulate's management efficiency
Cingulate has return on total asset (ROA) of (1.0433) % which means that it has lost $1.0433 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.7382) %, meaning that it created substantial loss on money invested by shareholders. Cingulate's management efficiency ratios could be used to measure how well Cingulate manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Cingulate's Return On Capital Employed is most likely to increase in the upcoming years. The Cingulate's current Return On Equity is estimated to increase to 3.24, while Return On Tangible Assets are forecasted to increase to (7.36). At this time, Cingulate's Other Current Assets are most likely to increase significantly in the upcoming years. The Cingulate's current Debt To Assets is estimated to increase to 0.85, while Net Tangible Assets are projected to decrease to roughly 2.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (104.72) | (99.49) | |
| Tangible Book Value Per Share | (104.72) | (99.49) | |
| Enterprise Value Over EBITDA | (0.39) | (0.41) | |
| Price Book Value Ratio | (1.16) | (1.10) | |
| Enterprise Value Multiple | (0.39) | (0.41) | |
| Price Fair Value | (1.16) | (1.10) | |
| Enterprise Value | 14 M | 12.5 M |
Leadership effectiveness at Cingulate is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cingulate insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cingulate's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cingulate insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cingulate Corporate Filings
8K | 24th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 22nd of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 15th of October 2024 Other Reports | ViewVerify |
Cingulate Earnings per Share Projection vs Actual
Cingulate Corporate Executives
Elected by the shareholders, the Cingulate's board of directors comprises two types of representatives: Cingulate inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cingulate. The board's role is to monitor Cingulate's management team and ensure that shareholders' interests are well served. Cingulate's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cingulate's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer CPA | Senior CFO | Profile | |
| Dr MBA | Executive COO | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cingulate. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Cingulate Stock please use our How to Invest in Cingulate guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cingulate. If investors know Cingulate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cingulate listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cingulate is measured differently than its book value, which is the value of Cingulate that is recorded on the company's balance sheet. Investors also form their own opinion of Cingulate's value that differs from its market value or its book value, called intrinsic value, which is Cingulate's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cingulate's market value can be influenced by many factors that don't directly affect Cingulate's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cingulate's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cingulate is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cingulate's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.